PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2022 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.



Thursday, August 18th

6:45 - 7:45 AM
EMERGING STRATEGIES IN HEMOPHILIA: RESTORING THE HEMOSTATIC BALANCE (SPONSORED BY CLINICAL CARE OPTIONS, LLC)
Chicago Ballroom VI

The 1.0-hour, CME-certified satellite symposium will include an engaging discussion on the management of hemophilia A and B. Expert faculty will use case discussions to highlight the challenges with factor VIII and factor IX replacement, the health burden of hemophilia care, and the need for more novel treatments. In addition, faculty will cover the future of hemophilia therapy, which includes novel therapies aimed at restoring hemostatic balance by blocking/targeting the tissue factor pathway inhibitor or antithrombin. The symposium will close with a panel discussion of key abstracts on hemophilia management from THSNA 2022 and an audience question and answer session.


RAISING THE BAR FOR PEOPLE WITH HEMOPHILIA AND INHIBITORS: CLINICIAN AND PATIENT PERSPECTIVES ON ACUTE BLEED MANAGEMENT WITH EPTACOG BETA (SPONSORED BY HEMA BIOLOGICS)
Chicago Ballroom IX-X

Inhibitor development remains the most serious complication of hemophilia A or B treatment, causing significant burden on the patient, their family, providers, and the healthcare system. Abundant prophylaxis and bleed treatment options exist for hemophilia patients without inhibitors, bringing health equity within reach. For patients with inhibitors, however, acute bleed management has lagged. Even for those on prophylaxis with non-replacement therapies, spontaneous and traumatic bleeding events are still a reality. Having different options for both prophylaxis and bleed control empowers clinicians to individualize and tailor treatment regimens, providing patients with opportunities to improve their clinical outcomes and pursue their life goals. The objectives of therapy are enabling individuals with inhibitors to participate in their life in the manner that they choose, and not be limited by their disease or by the treatment of their disease. Join a panel of experts, including an individual with hemophilia A and inhibitors, to discuss their clinical experience with eptacog beta and its contribution towards achieving health equity in patients with hemophilia A or B with inhibitors. The discussion will be moderated by Leonard A. Valentino, MD, and feature a subject matter expert who has thrived despite inhibitors, and Robert Sidonio Jr., MD.

8:00 - 9:30 AM
HORMONE THERAPY AND THROMBOSIS-HOT TOPICS IN SEX AND GENDER RELATED THROMBOSIS
Chair/Organizer: Vinai Bhagirath, Megan Brown
Sheraton Ballroom IV-V
INHIBITOR TESTING ISSUES
Chair/Organizer: Parul Bhargava, Bhavya Doshi
Chicago Ballroom VII
PAIN SCIENCE IN BLEEDING DISORDERS
Chair/Organizer: Michelle Witkop, Maria E Santaella
Sheraton Ballroom I-III
9:30 - 10:00 AM
BREAK
Ballroom Promenade
10:00 - 11:00 AM
SHORT TALKS - BLEEDING III
Chair/Organizer: Robert Sidonio, John Chiari
Sheraton Ballroom I-III

SHORT TALKS - PLATELETS, LEUKOCYTES & INFLAMMATION
Chair/Organizer: Anh T. Ngo, Kristi Smock
Chicago Ballroom VII

SHORT TALKS - THROMBOSIS CLINICAL AND SCIENCE II
Chair/Organizer: Katrien Devreese, Conroy O Field
Sheraton Ballroom IV-V
11:05 - 12:20 PM
ON THE CUTTING EDGE OF HEMOSTASIS AND THROMBOSIS
Chair/Organizer: Kristi Smock, Anne Rose
Sheraton Ballroom IV-V